In a significant move to consolidate its dominance in the clinical diagnostics market, Labcorp has announced a definitive agreement to acquire key laboratory assets from BioReference Health, a subsidiary of OPKO Health. The deal, valued at up to $872 million, marks a strategic pivot for both organizations: Labcorp aims to expand its nationwide testing infrastructure, while OPKO Health seeks to sharpen its focus on its core biopharmaceutical pipeline.
Main Facts: A Strategic Expansion
The transaction is structured as an $722 million upfront cash payment for a substantial portion of BioReference’s diagnostic portfolio. This includes critical operations spanning clinical laboratory services, women’s health testing, urology, and corrections-based diagnostics. As part of the acquisition, Labcorp will absorb more than 80 patient service centers, significantly increasing its physical footprint and reach across the United States.
Beyond the baseline assets, the deal includes a performance-based earnout provision of up to $150 million, contingent upon future revenue generated by the 4Kscore prostate cancer test. This proprietary blood test—a cornerstone of the acquisition—is designed to identify the probability of aggressive prostate cancer in men aged 45 and older. By integrating this technology, Labcorp positions itself to capture a larger share of the specialized oncology diagnostics market.
Chronology: The Path to Integration
The journey of the 4Kscore test, which serves as the primary catalyst for the earnout portion of this deal, reflects the evolving landscape of diagnostic regulation.
- 2014: The 4Kscore test is first introduced to the market as a laboratory-developed test (LDT), providing clinicians with an alternative to traditional methods of identifying prostate cancer risk.
- 2021: Following years of clinical data collection and rigorous review, the 4Kscore test receives formal US Food and Drug Administration (FDA) approval, validating its utility in helping physicians decide whether to proceed with invasive biopsies.
- 2026 (Q2): BioReference Health reports robust operational figures, with its diagnostics segment generating $74.5 million in revenue, of which $6.3 million is directly attributed to the 4Kscore test.
- Late 2026: Labcorp and OPKO Health finalize the acquisition agreement, setting the stage for a major transition in diagnostic service delivery.
While the timeline for the final integration remains subject to customary closing conditions and regulatory review, both parties have signaled a commitment to a seamless transition to ensure that patient care remains uninterrupted.
Supporting Data and Market Context
The scale of this acquisition is best understood when viewed through the lens of Labcorp’s massive operational volume. In 2025 alone, the North Carolina-headquartered giant performed more than 750 million tests globally. Furthermore, the company played a role in the development and approval of over 85% of all new drugs and therapeutic products sanctioned by the FDA during that year.
For OPKO Health, the diagnostics division has been a consistent, albeit capital-intensive, component of its business. The divestiture of these assets allows OPKO to streamline its corporate structure. With the diagnostics business moving to a company with the scale of Labcorp, OPKO’s leadership believes the 4Kscore test will achieve a market penetration that was previously constrained by the smaller footprint of BioReference.
The 4Kscore test itself fills a vital clinical gap. By analyzing four different prostate-specific kallikrein biomarkers in the blood, the test provides a personalized risk score. For a patient with an elevated prostate-specific antigen (PSA) level or a suspicious digital rectal examination, the 4Kscore can be the difference between undergoing an unnecessary, painful biopsy and pursuing active surveillance.
Official Responses: Aligning Visions
The leadership teams of both organizations have framed the deal as a “win-win” for stakeholders, providers, and patients.
Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, emphasized the company’s commitment to accessibility. “This transaction will strengthen our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers in the US,” Vaughn stated. He noted that the acquisition is not merely about physical assets but about “broadening access to innovative diagnostics such as the FDA-approved 4Kscore test,” ultimately enabling more informed clinical decision-making.
On the other side of the table, Phillip Frost, Chairman and CEO of OPKO Health, highlighted the strategic imperative of the divestiture. “Labcorp’s national scale and capabilities will broaden patient and provider access to BioReference’s 4Kscore test to many more patients across the country,” Dr. Frost remarked. “We believe this transaction is an important catalyst to further unlock additional value for our shareholders, allowing us to sharpen our focus on our biopharmaceutical initiatives.”
Implications for the Healthcare Landscape
Impact on Patient Care
For the average patient, the primary implication is an increase in the availability of high-level diagnostic services. By integrating BioReference’s specialized urology and women’s health services into Labcorp’s existing network, the company is effectively reducing geographic barriers to testing. Patients who previously had limited options for specific diagnostic panels may now find these services readily available at a local Labcorp center.
Competitive Dynamics
The diagnostic industry is currently in a phase of rapid consolidation. By acquiring these assets, Labcorp is effectively removing a competitor in the clinical testing space while simultaneously acquiring a high-value, specialized asset (4Kscore) that distinguishes its service offering from smaller regional laboratories. This move signals to the market that Labcorp is prioritizing high-margin, specialized testing to complement its high-volume, general diagnostic business.
The Shift to "Specialized Diagnostics"
The inclusion of the 4Kscore test underscores a broader industry shift: the movement away from generic testing toward precision medicine. As healthcare becomes more personalized, diagnostic providers must move beyond basic panels to offer tests that provide predictive insights into chronic and life-threatening conditions. The acquisition suggests that Labcorp intends to remain the primary partner for physicians who require actionable, data-driven diagnostic tools to manage complex patient populations.
Operational Streamlining for OPKO
For OPKO Health, the implications are equally profound. Managing a large-scale diagnostic laboratory requires a different operational model than drug development. By shedding these assets, OPKO can reallocate its capital and human resources toward the R&D and commercialization of its biopharmaceutical products. This is a common strategy in the life sciences sector, where firms often divest service-based divisions to focus on the higher-growth, higher-risk potential of novel therapeutics.
The Future of Laboratory-Developed Tests (LDTs)
The 4Kscore test’s history—from an LDT to an FDA-approved diagnostic—serves as a case study for the industry. As regulators increase their scrutiny of LDTs, companies like Labcorp that possess the resources to shepherd tests through the full FDA approval process will likely become the preferred acquirers for smaller innovators. This deal may encourage other diagnostics companies to focus on developing proprietary, FDA-cleared tests that carry higher valuations and greater market security.
Conclusion
The $872 million agreement between Labcorp and OPKO Health is more than a simple transfer of assets; it is a strategic repositioning of two significant players in the US healthcare market. While Labcorp reinforces its position as an indispensable provider of specialized diagnostic infrastructure, OPKO Health clears the path for a concentrated focus on biopharmaceutical innovation.
As the integration process begins, the industry will be watching to see how quickly Labcorp can scale the 4Kscore test and how successfully it can incorporate the 80+ patient service centers into its existing, expansive diagnostic network. For the patient, the promise remains the same: faster, more accessible, and increasingly sophisticated diagnostic data to support healthier outcomes.
About the Author
